Sugi Predict

Sugi Predict / Compounds / SCHEMBL930213

SCHEMBL930213

SCHEMBL930213

O=C(O)c1cccc(OC2CCCC2)c1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 4/20 0.59
▸ KAT6A Q92794 2/20 0.59
▸ PDE4A P27815 1/20 0.56
▸ PDE4B Q07343 1/20 0.56
▸ PDE4C Q08493 1/20 0.56
▸ PDE4D Q08499 1/20 0.56
▸ AKR1C3 P42330 1/20 0.54
▸ KMT2A Q03164 2/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ GRIK1 P39086 1/20 0.53
▸ GRIA2 P42262 1/20 0.53
▸ KMO O15229 1/20 0.53
▸ PKM P14618 1/20 0.51
▸ OPRK1 P41145 4/20 0.51
▸ OPRM1 P35372 1/20 0.51
▸ KCNH2 Q12809 1/20 0.51
▸ RAB9A P51151 2/20 0.48
▸ NR4A2 P43354 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30162751 1.00 EPHX2 (0.59) EPHX2KAT6APDE4APDE4BPDE4C
SCHEMBL9005535 0.98 EPHX2 (0.57) EPHX2KAT6APDE4APDE4BPDE4C
SCHEMBL930820 0.98 EPHX2 (0.57) EPHX2KAT6APDE4APDE4BPDE4C
SCHEMBL931638 0.98 EPHX2 (0.57) EPHX2KAT6APDE4APDE4BPDE4C
SCHEMBL30575465 0.98 EPHX2 (0.57) EPHX2KAT6APDE4APDE4BPDE4C
SCHEMBL931435 0.97 EPHX2 (0.59) EPHX2KAT6APDE4APDE4BPDE4C
SCHEMBL29505911 0.93 EPHX2 (0.65) EPHX2KAT6APDE4APDE4BPDE4C
SCHEMBL9005597 0.86 EPHX2 (0.58) EPHX2KAT6APDE4APDE4BPDE4C
SCHEMBL17573001 0.86 HRH1 (0.60) EPHX2KAT6AAKR1C3KMT2AMEN1
SCHEMBL1168318 0.86 EPHX2 (0.55) EPHX2KAT6AAKR1C3KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 — — WO claimed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 — — US claimed
EP-3110427-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE Urigen Pharmaceuticals, Inc. (US) 2017-01-04 — — EP claimed
WO-2015127416-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE URIGEN PHARMACEUTICALS, INC. (US) 2015-08-27 — — WO claimed
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 — — WO disclosed
CN-112812077-B Benzamide compound, preparation method thereof, pharmaceutical composition and application 中国科学院上海药物研究所 2023-08-22 — — CN disclosed
US-11572347-B2 Orally available sEH/PDE4 dual inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-02-07 — — US disclosed
US-11572347-B2 Orally available sEH/PDE4 dual inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-02-07 — — US disclosed
WO-2022051639-A1 STAT INHIBITORY COMPOUNDS AND COMPOSITIONS JANPIX LIMITED (US) 2022-03-10 — — WO disclosed
US-20210395202-A1 ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS GOETHE-UNIVERSITY FRANKFURT (DE) 2021-12-23 — — US disclosed
US-20210395202-A1 ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS GOETHE-UNIVERSITY FRANKFURT (DE) 2021-12-23 — — US disclosed
CN-112812077-A Benzamide compound and preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2021-05-18 — — CN disclosed
US-20050245551-A1 Amide derivatives ASTRAZENECA AB 2005-11-03 — — US disclosed
CN-1178932-C Amide derivatives — 2004-12-08 — — CN disclosed
CN-1350530-A Amide derivatives ASTRAZENECA AB (SE) 2002-05-22 — — CN disclosed
EP-1163237-A1 AMIDE DERIVATIVES AstraZeneca AB (SE) 2001-12-19 — — EP disclosed
WO-2000055153-A1 AMIDE DERIVATIVES ASTRAZENECA AB (SE) 2000-09-21 — — WO disclosed
EP-0579223-B1 Carboxylic acid derivatives having 5 alpha-reductase inhibitory activity MITSUBISHI CHEM CORP (JP) 1996-10-09 — — EP disclosed
US-5385917-A Treating androgen dependent diseases MITSUBISHI KASEI CORPORATION (JP) 1995-01-31 — — US disclosed
EP-0579223-A1 Carboxylic acid derivatives having 5 alpha-reductase inhibitory activity Mitsubishi Chemical Corporation (JP) 1994-01-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572347-B2 Orally available sEH/PDE4 dual inhibitors EPHX1, PDE4A, EPHX2 EPHX2 3/4885KAT6A 3394/4885PDE4A 2/4885
US-20050245551-A1 Amide derivatives IL6, IL6ST, IL1B EPHX2 277/4885KAT6A 518/4885PDE4A 3232/4885
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS SI, SLC20A1, SLC20A2 EPHX2 1952/4885KAT6A 4132/4885PDE4A 2687/4885
US-20210395202-A1 ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS EPHX1, PDE4A, EPHX2 EPHX2 3/4885KAT6A 3394/4885PDE4A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.